dc.contributor.author | Hashemilar, M | |
dc.contributor.author | Barzegar, M | |
dc.contributor.author | Nikanfar, M | |
dc.contributor.author | Bonyadi, MR | |
dc.contributor.author | Goldust, M | |
dc.contributor.author | Ramouz, A | |
dc.contributor.author | Ebrahimi, F | |
dc.date.accessioned | 2018-08-26T08:54:14Z | |
dc.date.available | 2018-08-26T08:54:14Z | |
dc.date.issued | 2013 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/54101 | |
dc.description.abstract | Objective: Antiganglioside antibodies have been reported to play a role in the pathophysiology of Guillain-Barrأ© syndrome (GBS). Methods: This case-control study was designed to evaluate the status of antiganglioside antibodies in children with GBS. The study included 50 patients suffering from GBS as the case group and 30 children as the control group. Clinical information such as demographic data and recent digestive or respiratory infection (within the last month) was collected for all patients, and paraclinical studies including cerebrospinal fluid examination and electrophysiology were conducted by a subspecialized physician. Anti-GM1, anti-GQ1 and anti-GD1a antibodies were measured with ELISA and the EUROLINE method. Results: The mean age of patients in the case and control groups was 5.3 آ± 3.8 and 5.4 آ± 3.4 years, respectively. With the EUROLINE method, the results obtained for anti-GM1 were significant (p = 0.007); however, the p values for anti-GQ1a and anti-GQ1b were not significant (0.051 vs. 0.94), while with ELISA, comparing all three antibodies in both the case and control groups showed statistically significant results, with a p < 0.05. Conclusion: EUROLINE is a new method used to evaluate antibodies in immune system diseases, but it is not useful for all antibodies specific to GBS, as the analysis was significant with a p value of 0.007 for anti-GM2. آ© 2013 S. Karger AG, Basel. | |
dc.language.iso | English | |
dc.relation.ispartof | NeuroImmunoModulation | |
dc.subject | ganglioside antibody | |
dc.subject | ganglioside GD1a antibody | |
dc.subject | ganglioside GM1 antibody | |
dc.subject | ganglioside GQ1 antibody | |
dc.subject | unclassified drug | |
dc.subject | ganglioside GD1b antibody | |
dc.subject | article | |
dc.subject | blood sampling | |
dc.subject | case control study | |
dc.subject | cerebrospinal fluid examination | |
dc.subject | child | |
dc.subject | clinical article | |
dc.subject | controlled study | |
dc.subject | demography | |
dc.subject | electrophysiology | |
dc.subject | enzyme linked immunosorbent assay | |
dc.subject | female | |
dc.subject | gastrointestinal infection | |
dc.subject | Guillain Barre syndrome | |
dc.subject | human | |
dc.subject | immunopathogenesis | |
dc.subject | male | |
dc.subject | pathophysiology | |
dc.subject | physician | |
dc.subject | preschool child | |
dc.subject | priority journal | |
dc.subject | respiratory tract infection | |
dc.subject | school child | |
dc.subject | antibody blood level | |
dc.subject | antibody detection | |
dc.subject | Article | |
dc.subject | childhood disease | |
dc.subject | controlled clinical trial | |
dc.subject | enzyme linked immunosorbent assay | |
dc.subject | EUROLINE method | |
dc.subject | Guillain Barre syndrome | |
dc.subject | intermethod comparison | |
dc.subject | predictive value | |
dc.subject | sensitivity and specificity | |
dc.subject | Western blotting | |
dc.subject | Antibodies | |
dc.subject | Child | |
dc.subject | Child, Preschool | |
dc.subject | Enzyme-Linked Immunosorbent Assay | |
dc.subject | Female | |
dc.subject | Gangliosides | |
dc.subject | Guillain-Barre Syndrome | |
dc.subject | Humans | |
dc.subject | Male | |
dc.subject | Retrospective Studies | |
dc.subject | Sensitivity and Specificity | |
dc.title | Evaluating the status of antiganglioside antibodies in children with Guillain-Barrأ© syndrome | |
dc.type | Article | |
dc.citation.volume | 21 | |
dc.citation.issue | 1 | |
dc.citation.spage | 64 | |
dc.citation.epage | 68 | |
dc.citation.index | Scopus | |
dc.identifier.DOI | https://doi.org/10.1159/000355830 | |